In Brief: Bio-Oxy warning letter
This article was originally published in The Tan Sheet
Executive Summary
Bio-Oxy warning letter: Saratoga, Calif.-based Bio-Life International receives April 2 warning letter from FDA's San Francisco district office citing "objectionable" drug claims made by the product, such as "effective against all viruses tested," "inactivating Herpes viruses," and "inhibitory to Saccharomyces species." FDA also notes that Bio-Oxy is misbranded as well as adulterated because it is recommended for use on pets, for which it is not approved, and for use in sterilizing hospital equipment and instruments, causing it to be a misbranded device. The company's "Professional Price List" additionally includes "objectionable claims" for some of its other products including Bee Pollen and Pycnogenol, the letter asserts...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning